Faes Farma continued on strong form into 2015, with results in line with the market and our expectations. Revenue was up 8.2% yoy to €51.4m, driven by the robust performance of the mature drug portfolio, Bilastine, animal nutrition, and international markets. The trickledown impact of the sturdy revenue growth alongside a favourable product mix – better performance from higher margin products – positively impacted the margins, with EBITDA growing 16.7% yoy (160bp yoy rise in
23 Jun 2015
Strong results; glad tidings from Japan
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong results; glad tidings from Japan
Faes Farma, S.A. (FFEA:FRA) | 0 0 2.0% | Mkt Cap: 765.7m
- Published:
23 Jun 2015 -
Author:
Jyoti Prakash -
Pages:
3
Faes Farma continued on strong form into 2015, with results in line with the market and our expectations. Revenue was up 8.2% yoy to €51.4m, driven by the robust performance of the mature drug portfolio, Bilastine, animal nutrition, and international markets. The trickledown impact of the sturdy revenue growth alongside a favourable product mix – better performance from higher margin products – positively impacted the margins, with EBITDA growing 16.7% yoy (160bp yoy rise in